Innovation | Print |

The Center has a high scientific and technical potential of modern research facilities, experimental equipment, which enables us to provide advice on diagnosis, treatment and prevention of tuberculosis and respiratory diseases, carry out comprehensive research in key areas, to ensure quality execution of research and development, development of practical results, and to train researchers.

During 2006-2010, the center carried out 26 jobs in the state integrated program of research "Modern Technologies in Medicine" program branch destination, aimed at ensuring the activities of ministries, state science and technology programs, "Therapeutic and diagnostic technology," "Infectious diseases biotechnology and microbiology "and" Heart and blood vessels, "and specialized scientific and technical programs," Rehabilitation Technology "," Medical rehabilitation and expertise, "" Healthy mother - healthy child "," Women's health - the welfare of the family and the state. " During the period under study performed in the framework of international research projects, 20 commercial contracts with the enterprises of the republic, 15 contracts with foreign partners.

Together with the UE "Unitechprom BSU" developed and implemented in the domestic production spirometers MAC-1. During 2006-2010. issued and sold to consumers more than 630 units totaling more than 4 million rubles mlrd.687. Spirometry MAC-1 equipped regional clinics, local hospitals, central city clinics, RSPC, military hospitals, TB clinics, health centers, universities, sports medicine clinics, schools in the country, as well as more than 48 vehicles delivered to Russia, Kazakhstan, the European Union. "Best new innovation introduced in the production of" MAC-1 was awarded a diploma degree 5, 4 gold medals at international and national exhibitions.

As part of the State Program of innovative development of Belarus for 2007 - 2010 years. based on the "Minsk Institute Radiomaterials" created a new domestic production of medical oxygen concentrators (MCF-23). During the period 2008-2010. issued and sold to consumers 165 units totaling more than 1 million rubles mlrd.155. Specified vehicles are equipped with Minsk City Clinical Hospital (10,2,3), district hospitals, Gomel, Vitebsk oblast clinical hospital, district centers, GU "RSPC Pulmonology and Phthisiology."


As part of the State Scientific-Technical Programme "Infectious diseases and microbiology biotechnology" in 2009 in conjunction with the State "RSPC epidemiology and microbiology," Educational Establishment "Belarusian State Medical University" developed and patented the domestic test system for molecular genetic diagnosis of tuberculosis and susceptibility to rifampicin (registration number MN-7.114557-0909, Reg. license number of MI-7.97674), intended for the diagnosis of tuberculosis and identification of drug resistance to rifampicin by real-time PCR, which allows to reduce time detection of tuberculosis and drug resistance of 1-3 months up to 2 days.

In 2010 the center has developed and patented the technology of complex treatment of multidrug-resistant pulmonary tuberculosis with the use of autologous mesenchymal stem cells and autologous dendritic cell cultures isolated from bone marrow, primed antigens of mycobacteria. The expected effectiveness of treatment across the country will be about 140 patients with MDR-TB, which will not require re-treatment. The direct economic impact of about $ 1,400,000 per year, given the fact that the course of medical treatment of a patient with MDR-TB costs the state about $ 10 thousand. In 2009-2010. implemented more than 20 such high-tech operations.


Due to the practical use of technology developed and patented in the center for 2006-2010. was carried out 87 high-tech medical care (reconstructive surgery on the organs of the urogenital system, thoracic surgery on the lung and pleura, including using videoassistirovannyh operations), which contributed to the problems of import substitution, improved diagnosis, treatment and prevention of AML, as well as the challenging task of reducing mortality and improving quality of life of patients.

In 2006-2010. Center staff participated in 13 international and national exhibitions, 218 reports made by 75 international and national conferences. Received more than 90 certificate members. During the reporting period in the establishment of a Centre for training and education of staff, prepared and conducted seven research conferences, VII Congress of TB specialists, more than 75 training seminars. In the workplace, prepared by 121 personnel. According to the research received 11 titles on the objects of industrial property rights (in 2010. - 3). Posted 9 of textbooks, 252 articles in scientific journals (in 2010. - 66), including overseas - 9. Created 36 advanced manufacturing technologies (36 - new in the country). For 5 years at the center are protected by a doctoral and three master's theses. There is a positive dynamics of basic indicators of scientific, technical and innovation activities of the Centre. (Common graphics for 2011).


Actively developing international scientific cooperation. In 2011 began studies in the three international research projects. The study of gene expression profiles, and immunological parameters in tuberculosis in the treatment process is carried out by Belarusian scientists together with the Institute for Infection Biology in Berlin (Germany), an international observational study of tuberculosis among HIV-positive patients - with the Panum Institute, Copenhagen (Denmark), the analysis of MDR -TB in the Russian Federation and the Republic of Belarus - with the Central Research Institute of Tuberculosis, RAMS (Moscow). Since 2009, the Center collaborates with the Swedish Institute for Infectious Disease Control (Stockholm) to study the effectiveness of using modern immunological and molecular genetic methods.

For his achievements in research and innovation center scientists were awarded the medal "For Labour Merits", 10 signs of the "Excellent Health", 2 diplomas of the Council of Ministers of the Republic of Belarus, three personal allowances in Science for his outstanding contribution to the socio-economic development of the country.

Research, Science and Technology and Innovation Centre meets its statutory objectives and performed at a high level.

In 2013, a pilot study was launched for the first time: “To develop a method for cell therapy with multipotent mesenchymal stromal cells (MMSC) for the treatment of extensively drug-resistant tuberculosis (XDR)” (as part of the state scientific and technical program “Infection and Microbiological Nanobiotechnology”). The results of this work have been widely recognized in the global community and an international publication has been made : Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial / Skrahin A., Ahmed R.K., Ferrara G., Rane L., Poiret T., Isaikina Y., Skrahina A., Zumla A., Maeurer M.J. // Lancet Respir Med. 2014 Feb;2(2):108-22. doi: 10.1016/S2213-2600(13)70234-0. Epub 2014 Jan .

Since 2014, in the framework of the research project “Develop an immunotherapy method for patients with COPD and and idiopathic pulmonary fibrosis using autologous MMSK” (as part of the task State Scientific and Technical Program "New Technologies for Diagnostics, Treatment and Prevention," Subprogram "Transplantology and Regenerative Medicine" for the first time in the Republic of Belarus by the authors Litskevich L.V., Skryagin A.E., Isaikina Y.I. and  others, Experimental studies were initiated on the use of autologous MMSC in the complex treatment of patients with COPD and idiopathic pulmonary fibrosis.

This work was carried out as part of the “Developing and implementing methods for the integrated treatment of patients with drug-resistant tuberculosis, COPD using re-introduction of MMSK” in 2017-2018.

The experience of the double use of autologous MMSK in the complex treatment of patients with COPD in the Republic of Belarus indicates the absence of adverse reactions and complications on the introduction of MMSC, which confirms the safety of the method.

There was a significant increase in the walking distance in 6MWT (in the 6-minute step test) in patients with COPD by 9.4% after repeated administration of MMSC from 391.5 ± 0.9 m to 428.3 ± 1.04 m ( p <0.001). Significant improvement of the hemodynamic parameters of the cardiovascular system, namely, the normalization of the  systolic BP, by 14.8% from 150.0 ± 2.1 to 127.8 ± 2.5 (p <0.001);  diastolic BP is 13.2% from 95.0 ± 1.0 to 82.5 ± 1.4 (p <0.001). It was noted: an increase in the total number of T-lymphocytes in both percentage and absolute content (p> 0.05), a pronounced tendency for an increase of 13.4% in T-helpers (CD4 +) from 37.8 ± 2.87% to 42.86 ± 3.41; increase in immunoregulatory index by 28% (p> 0.05).

The positive effect of the method is characterized by: a decrease in the severity of disabling disorders (respiratory failure, a decrease in the severity of shortness of breath according to the MRC scale by an average of 37%), a decrease in the severity of the residual lung volume by 6.2% (p <0.001), which indicates an improvement airway patency, reducing the inflammatory component of bronchial obstruction, improving the quality of life of patients by 25%, helps to reduce the number of 80.0% and the severity of exacerbations of COPD.

According to the results of the research, the Ministry of Health approved the instructions for use: “The method of cell therapy for chronic obstructive pulmonary disease and idiopathic fibrosing alveolitis using autologous multipotent mesenchymal stromal cells” (reg. No. 204-1215 of November 29, 2015); "Method for the integrated treatment of patients with COPD using twofold administration of autologous multiprotent mesenchymal stromal cells", reg. №159-1118from 14.12.2018 Received 5 acts of implementation.

Patent for invention No. 21852 was received on application No. 20150567 / Method for combined therapy of chronic obstructive pulmonary disease // Litskevich L.V., Gurevich G.L., Skryagin A.E., Shpakovskaya N.S., Skryagina E.M., Novikova MA, Isaykina Ya.I. from 01.29.2018.

Poster report made Litskevich L., Skrahin A., Shpacovskaya N., Solodovnicova V., Isaikina J. / Effectiveness of mesenchimal stem cells in the treatment  of patients with chronical obstructive pulmonary disease in Belarus // ЕRC, Mijan.– 2017. –№1283.